Boeh Ing RLS drug comparable to placebo

New data presented at the annual meeting of the American Academy of Neurology, in Seattle, Washington, show that augmentation did not  significantly differ in restless legs syndrome patients treated with  Boehringer Ingleheim's Mirapexin/Sifrol (pramipexole) versus the group  receiving placebo.

The German drugmaker said that results from the study presented at the  AAN also showed sustained efficacy for pramipexole over a long-term  period. Positive response to treatment in this randomized,  placebo-controlled, double-blind trial was significantly higher for  pramipexole compared to placebo.